Treatment of advanced prostatic carcinoma with D‐trp‐6‐LH‐RH

David Gonzalez‐Barcena, Patricia Perez‐Sanchez, Sergio Ureta‐Sanchez, Hector Berea Dominguez, Alicia Graef‐Sanchez, Margarita Becerril Morales, Ana Maria Comaru‐Schally, Andrew V Schally

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Twenty patients with stage D2 prostatic carcinoma were treated for up to 18 months with D‐Trp‐6‐LH‐RH. Results of more than 3 months of treatment on these 20 patients are reported. The analog was given SC once daily at a dose of 1,000 μg/day. All patients had bone pain and high levels of acid and alkaline phosphatase. After the first week of D‐Trp‐6‐LH‐RH administration, major decreases in bone pain and reversal of the signs of prostatism were observed. Acid phosphatase gradually fell, achieving normal values after 12 weeks. Initial plasma testosterone was within normal limits, but during treatment with D‐Trp‐6‐LH‐RH it fell to castration levels. Resting values of PRL, GH, TSH, and cortisol did not show significant changes. After TRH, TSH increased in five patients, but five did not respond. However, at 2 and 4 months, all patients released TSH in response to TRH. Two patients died during the treatment with D‐Trp‐6‐LH‐RH despite initial subjective responses and decreases in testosterone levels. The rise in acid phosphatase levels in these two patients was accompanied by a general deterioration, suggesting that they had androgen‐independent cancer. One patient who developed progressive hepatic, bone, and pulmonary metastases in spite of previous orchiectomy was also treated with the analog. Three months later his acid phosphatase levels were within normal values, and partial regression of metastases was observed. These results demonstrate that D‐Trp‐6‐LH‐RH and other LH‐RH agonists can be used as an effective endocrine therapy for advanced prostate carcinoma, thereby avoiding the side effects of estrogens or the psychological impact of surgical castration.

Original languageEnglish (US)
Pages (from-to)21-30
Number of pages10
JournalProstate
Volume7
Issue number1
DOIs
StatePublished - 1985
Externally publishedYes

Fingerprint

Carcinoma
Acid Phosphatase
Castration
Therapeutics
Bone and Bones
Testosterone
Reference Values
Prostatism
Neoplasm Metastasis
Pain
Orchiectomy
Gonadotropin-Releasing Hormone
Alkaline Phosphatase
Hydrocortisone
Prostate
Estrogens
Psychology
Lung
Liver
Neoplasms

Keywords

  • agonists of LH‐RH
  • androgen‐dependent prostate tumors
  • cancer
  • hypothalamic hormones
  • prostate gland

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Gonzalez‐Barcena, D., Perez‐Sanchez, P., Ureta‐Sanchez, S., Dominguez, H. B., Graef‐Sanchez, A., Morales, M. B., ... Schally, A. V. (1985). Treatment of advanced prostatic carcinoma with D‐trp‐6‐LH‐RH. Prostate, 7(1), 21-30. https://doi.org/10.1002/pros.2990070104

Treatment of advanced prostatic carcinoma with D‐trp‐6‐LH‐RH. / Gonzalez‐Barcena, David; Perez‐Sanchez, Patricia; Ureta‐Sanchez, Sergio; Dominguez, Hector Berea; Graef‐Sanchez, Alicia; Morales, Margarita Becerril; Comaru‐Schally, Ana Maria; Schally, Andrew V.

In: Prostate, Vol. 7, No. 1, 1985, p. 21-30.

Research output: Contribution to journalArticle

Gonzalez‐Barcena, D, Perez‐Sanchez, P, Ureta‐Sanchez, S, Dominguez, HB, Graef‐Sanchez, A, Morales, MB, Comaru‐Schally, AM & Schally, AV 1985, 'Treatment of advanced prostatic carcinoma with D‐trp‐6‐LH‐RH', Prostate, vol. 7, no. 1, pp. 21-30. https://doi.org/10.1002/pros.2990070104
Gonzalez‐Barcena D, Perez‐Sanchez P, Ureta‐Sanchez S, Dominguez HB, Graef‐Sanchez A, Morales MB et al. Treatment of advanced prostatic carcinoma with D‐trp‐6‐LH‐RH. Prostate. 1985;7(1):21-30. https://doi.org/10.1002/pros.2990070104
Gonzalez‐Barcena, David ; Perez‐Sanchez, Patricia ; Ureta‐Sanchez, Sergio ; Dominguez, Hector Berea ; Graef‐Sanchez, Alicia ; Morales, Margarita Becerril ; Comaru‐Schally, Ana Maria ; Schally, Andrew V. / Treatment of advanced prostatic carcinoma with D‐trp‐6‐LH‐RH. In: Prostate. 1985 ; Vol. 7, No. 1. pp. 21-30.
@article{c7d29c17845340babdbd5e12eb33d829,
title = "Treatment of advanced prostatic carcinoma with D‐trp‐6‐LH‐RH",
abstract = "Twenty patients with stage D2 prostatic carcinoma were treated for up to 18 months with D‐Trp‐6‐LH‐RH. Results of more than 3 months of treatment on these 20 patients are reported. The analog was given SC once daily at a dose of 1,000 μg/day. All patients had bone pain and high levels of acid and alkaline phosphatase. After the first week of D‐Trp‐6‐LH‐RH administration, major decreases in bone pain and reversal of the signs of prostatism were observed. Acid phosphatase gradually fell, achieving normal values after 12 weeks. Initial plasma testosterone was within normal limits, but during treatment with D‐Trp‐6‐LH‐RH it fell to castration levels. Resting values of PRL, GH, TSH, and cortisol did not show significant changes. After TRH, TSH increased in five patients, but five did not respond. However, at 2 and 4 months, all patients released TSH in response to TRH. Two patients died during the treatment with D‐Trp‐6‐LH‐RH despite initial subjective responses and decreases in testosterone levels. The rise in acid phosphatase levels in these two patients was accompanied by a general deterioration, suggesting that they had androgen‐independent cancer. One patient who developed progressive hepatic, bone, and pulmonary metastases in spite of previous orchiectomy was also treated with the analog. Three months later his acid phosphatase levels were within normal values, and partial regression of metastases was observed. These results demonstrate that D‐Trp‐6‐LH‐RH and other LH‐RH agonists can be used as an effective endocrine therapy for advanced prostate carcinoma, thereby avoiding the side effects of estrogens or the psychological impact of surgical castration.",
keywords = "agonists of LH‐RH, androgen‐dependent prostate tumors, cancer, hypothalamic hormones, prostate gland",
author = "David Gonzalez‐Barcena and Patricia Perez‐Sanchez and Sergio Ureta‐Sanchez and Dominguez, {Hector Berea} and Alicia Graef‐Sanchez and Morales, {Margarita Becerril} and Comaru‐Schally, {Ana Maria} and Schally, {Andrew V}",
year = "1985",
doi = "10.1002/pros.2990070104",
language = "English (US)",
volume = "7",
pages = "21--30",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Treatment of advanced prostatic carcinoma with D‐trp‐6‐LH‐RH

AU - Gonzalez‐Barcena, David

AU - Perez‐Sanchez, Patricia

AU - Ureta‐Sanchez, Sergio

AU - Dominguez, Hector Berea

AU - Graef‐Sanchez, Alicia

AU - Morales, Margarita Becerril

AU - Comaru‐Schally, Ana Maria

AU - Schally, Andrew V

PY - 1985

Y1 - 1985

N2 - Twenty patients with stage D2 prostatic carcinoma were treated for up to 18 months with D‐Trp‐6‐LH‐RH. Results of more than 3 months of treatment on these 20 patients are reported. The analog was given SC once daily at a dose of 1,000 μg/day. All patients had bone pain and high levels of acid and alkaline phosphatase. After the first week of D‐Trp‐6‐LH‐RH administration, major decreases in bone pain and reversal of the signs of prostatism were observed. Acid phosphatase gradually fell, achieving normal values after 12 weeks. Initial plasma testosterone was within normal limits, but during treatment with D‐Trp‐6‐LH‐RH it fell to castration levels. Resting values of PRL, GH, TSH, and cortisol did not show significant changes. After TRH, TSH increased in five patients, but five did not respond. However, at 2 and 4 months, all patients released TSH in response to TRH. Two patients died during the treatment with D‐Trp‐6‐LH‐RH despite initial subjective responses and decreases in testosterone levels. The rise in acid phosphatase levels in these two patients was accompanied by a general deterioration, suggesting that they had androgen‐independent cancer. One patient who developed progressive hepatic, bone, and pulmonary metastases in spite of previous orchiectomy was also treated with the analog. Three months later his acid phosphatase levels were within normal values, and partial regression of metastases was observed. These results demonstrate that D‐Trp‐6‐LH‐RH and other LH‐RH agonists can be used as an effective endocrine therapy for advanced prostate carcinoma, thereby avoiding the side effects of estrogens or the psychological impact of surgical castration.

AB - Twenty patients with stage D2 prostatic carcinoma were treated for up to 18 months with D‐Trp‐6‐LH‐RH. Results of more than 3 months of treatment on these 20 patients are reported. The analog was given SC once daily at a dose of 1,000 μg/day. All patients had bone pain and high levels of acid and alkaline phosphatase. After the first week of D‐Trp‐6‐LH‐RH administration, major decreases in bone pain and reversal of the signs of prostatism were observed. Acid phosphatase gradually fell, achieving normal values after 12 weeks. Initial plasma testosterone was within normal limits, but during treatment with D‐Trp‐6‐LH‐RH it fell to castration levels. Resting values of PRL, GH, TSH, and cortisol did not show significant changes. After TRH, TSH increased in five patients, but five did not respond. However, at 2 and 4 months, all patients released TSH in response to TRH. Two patients died during the treatment with D‐Trp‐6‐LH‐RH despite initial subjective responses and decreases in testosterone levels. The rise in acid phosphatase levels in these two patients was accompanied by a general deterioration, suggesting that they had androgen‐independent cancer. One patient who developed progressive hepatic, bone, and pulmonary metastases in spite of previous orchiectomy was also treated with the analog. Three months later his acid phosphatase levels were within normal values, and partial regression of metastases was observed. These results demonstrate that D‐Trp‐6‐LH‐RH and other LH‐RH agonists can be used as an effective endocrine therapy for advanced prostate carcinoma, thereby avoiding the side effects of estrogens or the psychological impact of surgical castration.

KW - agonists of LH‐RH

KW - androgen‐dependent prostate tumors

KW - cancer

KW - hypothalamic hormones

KW - prostate gland

UR - http://www.scopus.com/inward/record.url?scp=0022254343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022254343&partnerID=8YFLogxK

U2 - 10.1002/pros.2990070104

DO - 10.1002/pros.2990070104

M3 - Article

C2 - 2934692

AN - SCOPUS:0022254343

VL - 7

SP - 21

EP - 30

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 1

ER -